Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
$4.21
$2.41
$78.82
$504.98MN/A2.27 million shs22,357 shs
Immunocore Holdings plc stock logo
IMCR
Immunocore
$34.68
-2.7%
$31.06
$23.15
$41.54
$1.74B0.83362,037 shs435,478 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$4.92
-4.8%
$4.89
$3.79
$12.36
$2.00B0.8415.04 million shs37.44 million shs
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$33.52
-0.3%
$34.05
$27.12
$60.90
$2.01B2.38976,408 shs737,672 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
0.00%0.00%0.00%0.00%0.00%
Immunocore Holdings plc stock logo
IMCR
Immunocore
0.00%-6.90%+19.34%+20.42%-14.43%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%-10.38%+15.76%-22.52%-47.10%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.00%+6.18%+11.36%-16.12%-36.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Immunocore Holdings plc stock logo
IMCR
Immunocore
3.0429 of 5 stars
4.30.00.00.03.44.20.0
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
1.9289 of 5 stars
3.21.00.00.03.01.70.6
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
4.1079 of 5 stars
4.41.00.04.42.20.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
0.00
N/AN/AN/A
Immunocore Holdings plc stock logo
IMCR
Immunocore
2.55
Moderate Buy$58.8969.81% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.33
Hold$7.6054.47% Upside
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4050.36% Upside

Current Analyst Ratings Breakdown

Latest ADGI, RXRX, IMCR, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Immunocore Holdings plc stock logo
IMCR
Immunocore
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00
5/27/2025
Immunocore Holdings plc stock logo
IMCR
Immunocore
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00
5/8/2025
Immunocore Holdings plc stock logo
IMCR
Immunocore
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.00
5/6/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $8.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
4/14/2025
Immunocore Holdings plc stock logo
IMCR
Immunocore
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.00
4/10/2025
Immunocore Holdings plc stock logo
IMCR
Immunocore
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$71.00 ➝ $71.00
4/10/2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
N/AN/AN/AN/A$5.02 per shareN/A
Immunocore Holdings plc stock logo
IMCR
Immunocore
$333.58M5.22N/AN/A$7.42 per share4.67
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$59.82M33.44N/AN/A$1.98 per share2.48
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$347.68M5.78N/AN/A$7.64 per share4.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
-$226.79M-$3.15N/AN/AN/AN/A-57.14%-50.28%N/A
Immunocore Holdings plc stock logo
IMCR
Immunocore
-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%8/6/2025 (Estimated)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$328.07M-$1.77N/AN/AN/A-579.52%-76.56%-55.68%8/6/2025 (Estimated)
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-59.76%-32.69%-25.25%8/1/2025 (Estimated)

Latest ADGI, RXRX, IMCR, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Immunocore Holdings plc stock logo
IMCR
Immunocore
-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million
5/5/2025Q1 2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 million
5/5/2025Q2 2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
N/AN/AN/AN/AN/A
Immunocore Holdings plc stock logo
IMCR
Immunocore
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
N/A
7.09
7.09
Immunocore Holdings plc stock logo
IMCR
Immunocore
1.03
3.78
3.76
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.04
4.35
4.35
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.03
4.96
4.62

Institutional Ownership

CompanyInstitutional Ownership
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
96.94%
Immunocore Holdings plc stock logo
IMCR
Immunocore
84.50%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
N/A
Immunocore Holdings plc stock logo
IMCR
Immunocore
10.40%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
8.43%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adagio Therapeutics, Inc. stock logo
ADGI
Adagio Therapeutics
2,021108.83 millionN/ANot Optionable
Immunocore Holdings plc stock logo
IMCR
Immunocore
32050.23 million45.48 millionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400406.50 million329.18 millionOptionable
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
99059.92 million57.86 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adagio Therapeutics stock logo

Adagio Therapeutics NASDAQ:ADGI

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Immunocore stock logo

Immunocore NASDAQ:IMCR

$34.68 -0.95 (-2.67%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$34.63 -0.05 (-0.14%)
As of 06/13/2025 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$4.92 -0.25 (-4.84%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$4.93 +0.01 (+0.30%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$33.52 -0.11 (-0.33%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$33.51 -0.02 (-0.04%)
As of 06/13/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.